Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Drug Resistance

  Free Subscription

Articles published in Int J Antimicrob Agents

Retrieve available abstracts of 143 articles:
HTML format

Single Articles

    October 2021
  1. BOAS DO PRADO GV, Mendes ET, Martins RCR, Perdigao-Neto LV, et al
    Phenotypic and genotypic characteristics of a Carbapenem-resistant Serratia marcescens cohort and outbreak: describing an opportunistic pathogen.
    Int J Antimicrob Agents. 2021 Oct 26:106463.
    PubMed     Abstract available

  2. UDE Z, Flothkotter N, Sheehan G, Brennan M, et al
    Multi-Targeted Metallo-Ciprofloxacin Derivatives Rationally Designed and Developed to Overcome Antimicrobial Resistance.
    Int J Antimicrob Agents. 2021 Oct 10:106449.
    PubMed     Abstract available

    September 2021
  3. MAGALLON J, Vu P, Reeves C, Kwan S, et al
    Amikacin in combination with zinc pyrithione prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae isolate.
    Int J Antimicrob Agents. 2021 Sep 19:106442.

  4. CASTANHEIRA M, Doyle TB, Deshpande LM, Mendes RE, et al
    Activity of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem-Relebactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals.
    Int J Antimicrob Agents. 2021 Sep 18:106439.
    PubMed     Abstract available

  5. RUSSO A, Venditti M
    Vertebral osteomyelitis caused by vancomycin-resistant Enterococcus spp: a case series.
    Int J Antimicrob Agents. 2021 Sep 12:106432.

    August 2021
  6. KIM JS, Yu JK, Jeon SJ, Park SH, et al
    Distribution of mcr genes among carbapenem-resistant Enterobacterales clinical isolates: High prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea.
    Int J Antimicrob Agents. 2021 Aug 12:106418.
    PubMed     Abstract available

  7. ALLEN GP, Deao KM, Hill SA, Schipelliti SM, et al
    In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
    Int J Antimicrob Agents. 2021 Aug 12:106417.
    PubMed     Abstract available

  8. IWU CD, Patrick SM
    An insight into the Implementation of the Global Action Plan on Antimicrobial Resistance in the WHO African Region: A Roadmap for Action.
    Int J Antimicrob Agents. 2021 Aug 6:106411.
    PubMed     Abstract available

  9. LU S, Li D, Wang L, Bi Y, et al
    Promoter variations associated with expression of mcr-1 gene and level of colistin resistance.
    Int J Antimicrob Agents. 2021;58:106371.
    PubMed     Abstract available

  10. LI J, Roberts J
    Antibiotic pharmacokinetics/pharmacodynamics: where are we heading?
    Int J Antimicrob Agents. 2021;58:106369.

  11. JUNCO SJ, Bowman MC, Turner RB
    Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
    Int J Antimicrob Agents. 2021;58:106367.
    PubMed     Abstract available

  12. RAO GG, Landersdorfer CB
    Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond.
    Int J Antimicrob Agents. 2021;58:106368.
    PubMed     Abstract available

    July 2021
  13. WARETH G, Linde J, Hammer P, Nguyen NH, et al
    Corrigendum to "Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam" [International Journal of Antimicrobial Agents, Volume 56, Issue 4, October 2020, 1061
    Int J Antimicrob Agents. 2021 Jul 26:106407.

  14. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
    Erratum to "Impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries. A systematic review" [International Journal of Antimicrobial Agents (2021) Volume 58, Issue 1/106364].
    Int J Antimicrob Agents. 2021 Jul 14:106396.

  15. ANTONELLO RM, Di Bella S, Betts J, La Ragione R, et al
    Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales.
    Int J Antimicrob Agents. 2021;58:106362.
    PubMed     Abstract available

  16. LAI CC, Yu WL
    Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998-2019.
    Int J Antimicrob Agents. 2021;58:106354.
    PubMed     Abstract available

    June 2021
  17. LEE YL, Ko WC, Lee WS, Lu PL, et al
    In vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline, and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Res
    Int J Antimicrob Agents. 2021 Jun 21:106377.
    PubMed     Abstract available

  18. CHAIYACHAT P, Chaiprasert A, Nonghanphithak D, Smithtikarn S, et al
    Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance.
    Int J Antimicrob Agents. 2021 Jun 20:106385.
    PubMed     Abstract available

  19. MOOR J, Aebi S, Rickli S, Mostacci N, et al
    Dynamics of extended-spectrum cephalosporin-resistant E. coli in pig farms: A longitudinal study.
    Int J Antimicrob Agents. 2021 Jun 19:106382.
    PubMed     Abstract available

  20. TIMMERMANS M, Wattiau P, Denis O, Boland C, et al
    Colistin resistance genes mcr-1 to mcr-5, including a case of triple occurrence (mcr-1, -3 and -5), in Escherichia coli isolates from faeces of healthy pigs, cattle and poultry in Belgium, 2012-2016.
    Int J Antimicrob Agents. 2021;57:106350.
    PubMed     Abstract available

  21. CLERICI D, Oltolini C, Greco R, Ripa M, et al
    The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    Int J Antimicrob Agents. 2021;57:106335.
    PubMed     Abstract available

  22. ALMANGOUR TA, Garcia E, Zhou Q, Forrest A, et al
    Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
    Int J Antimicrob Agents. 2021;57:106328.
    PubMed     Abstract available

    May 2021
  23. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
    What is the impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries? A systematic review: AR after mass/systematic antibiotic administration.
    Int J Antimicrob Agents. 2021 May 24:106364.
    PubMed     Abstract available

  24. DELORY T, Gravier S, Pluart DL, Gaube G, et al
    Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Int J Antimicrob Agents. 2021 May 14:106361.
    PubMed     Abstract available

  25. TSAI HY, Lee YL, Liu PY, Lu MC, et al
    Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019/2020 Nationwide Surveillance of Multicenter Antimicrobial Re
    Int J Antimicrob Agents. 2021 May 4:106353.
    PubMed     Abstract available

  26. MEI CY, Wu H, Wang Y, Wang ZY, et al
    First detection of the multiresistance gene cfr in Escherichia coli from retail vegetables, China.
    Int J Antimicrob Agents. 2021;57:106348.

  27. MBHELE N, Chimukangara B, Gordon M
    HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
    Int J Antimicrob Agents. 2021;57:106343.
    PubMed     Abstract available

  28. WANG X, Ling Z, Sun N, Liu Y, et al
    Molecular genetic characteristics of mcr-9-harbouring Salmonella enterica serotype Typhimurium isolated from raw milk.
    Int J Antimicrob Agents. 2021;57:106332.
    PubMed     Abstract available

  29. NGUYEN HT, Venter H, Veltman T, Williams R, et al
    In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens.
    Int J Antimicrob Agents. 2021;57:106323.
    PubMed     Abstract available

  30. MUSHTAQ S, Garello P, Vickers A, Woodford N, et al
    Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Int J Antimicrob Agents. 2021;57:106318.
    PubMed     Abstract available

    April 2021
  31. KOSTYANEV T, Xavier BB, Garcia-Castillo M, Lammens C, et al
    Phenotypic and Molecular Characterisations of Carbapenem-resistant Acinetobacter baumannii Isolates Collected within the EURECA Study.
    Int J Antimicrob Agents. 2021 Apr 19:106345.
    PubMed     Abstract available

  32. HUANG PH, Cheng YH, Chen WY, Juan CH, et al
    Risk factors and mechanisms of in vivo emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2021 Apr 14:106342.
    PubMed     Abstract available

  33. CREMET L, Leroy AG, Muller D, Delanou S, et al
    Antibiotic Resistance Heterogeneity and LasR Diversity within Pseudomonas aeruginosa Populations from Pneumonia in Intensive Care Unit Patients.
    Int J Antimicrob Agents. 2021 Apr 12:106341.
    PubMed     Abstract available

  34. SCUDELLER L, Righi E, Chiamenti M, Bragantini D, et al
    Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Int J Antimicrob Agents. 2021 Apr 12:106344.
    PubMed     Abstract available

  35. TANG SSL, Chee E, Teo JQ, Chlebicki MP, et al
    Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study.
    Int J Antimicrob Agents. 2021 Apr 12:106340.
    PubMed     Abstract available

  36. KLEIN S, Boutin S, Heeg K, Zanger P, et al
    Genomic structure of ST8-t008 USA300 and USA300-LV MRSA in the Rhine-Neckar Region, Germany, 2012-2018.
    Int J Antimicrob Agents. 2021;57:106312.
    PubMed     Abstract available

  37. HERRERA M, Gregorio SD, Haim MS, Posse G, et al
    Genetic changes associated with tigecycline resistance in Staphylococcus aureus in vitro-selected mutants belonging to different lineages.
    Int J Antimicrob Agents. 2021;57:106304.
    PubMed     Abstract available

    March 2021
  38. HAGIHARA M, Kato H, Sugano T, Okade H, et al
    Pharmacodynamic evaluation of meropenem, cefepime, and aztreonam combined with a novel beta-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh in
    Int J Antimicrob Agents. 2021 Mar 28:106330.
    PubMed     Abstract available

  39. MAEHANA S, Eda R, Hirabayashi A, Niida N, et al
    nNatural factories that manufacture antimicrobial resistance genes: quadruple blaGES-carrying plasmids in Aeromonas and Pseudomonas species.
    Int J Antimicrob Agents. 2021 Mar 28:106327.

  40. YEAGER SD, Oliver JE, Shorman MA, Wright LR, et al
    Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections.
    Int J Antimicrob Agents. 2021 Mar 27:106329.
    PubMed     Abstract available

  41. LAI CC, Chen SY, Ko WC, Hsueh PR, et al
    Increased antimicrobial resistance during the COVID-19 pandemic.
    Int J Antimicrob Agents. 2021 Mar 18:106324.
    PubMed     Abstract available

  42. HALA S, Antony CP, Momin AA, Alshehri M, et al
    Co-occurrence of mcr-1 and mcr-8 genes in multi-drug-resistant Klebsiella pneumoniae from a 2015 clinical isolate.
    Int J Antimicrob Agents. 2021;57:106303.

  43. BONNIN RA, Girlich D, Jousset AB, Emeraud C, et al
    Genomic analysis of VIM-2-producing Enterobacter hormaechei subsp. steigerwaltii.
    Int J Antimicrob Agents. 2021;57:106285.
    PubMed     Abstract available

  44. NI M, Zhao L, Zhang WJ, Ma JW, et al
    Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration alone in intracranial infections.
    Int J Antimicrob Agents. 2021;57:106281.
    PubMed     Abstract available

  45. JOHNSON MG, Bruno C, Castanheira M, Yu B, et al
    Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Int J Antimicrob Agents. 2021;57:106278.
    PubMed     Abstract available

  46. VAN BILSEN WPH, van Dulm E, Matser A, Linde I, et al
    High carriage of ESBL-producing Enterobacteriaceae associated with sexual activity among men who have sex with men.
    Int J Antimicrob Agents. 2021;57:106276.
    PubMed     Abstract available

  47. BALANDIN B, Ballesteros D, Ruiz de Luna R, Lopez-Vergara L, et al
    Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
    Int J Antimicrob Agents. 2021;57:106270.
    PubMed     Abstract available

    Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences.
    Int J Antimicrob Agents. 2021;57:106257.
    PubMed     Abstract available

    Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences.
    Int J Antimicrob Agents. 2021;57:106258.
    PubMed     Abstract available

    February 2021
  50. JOHNSON TM, Molina KC, Miller MA, Kiser TH, et al
    Combination Ceftaroline and Daptomycin Salvage Therapy for Complicated Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Compared with Standard of Care.
    Int J Antimicrob Agents. 2021 Feb 17:106310.
    PubMed     Abstract available

  51. HU Y, Coates A
    Mefloquine enhances the activity of colistin against antibiotic-resistant Enterobacterales in vitro and in vivo animal studies.
    Int J Antimicrob Agents. 2021 Feb 17:106309.
    PubMed     Abstract available

  52. FUKUDA A, Nakamura H, Umeda K, Yamamoto K, et al
    Seven-year surveillance of the prevalence of antimicrobial-resistant Escherichia coli isolates, with a focus on ST131 clones, among healthy people in Osaka, Japan.
    Int J Antimicrob Agents. 2021 Feb 5:106298.
    PubMed     Abstract available

  53. HERNANDEZ-GARCIA M, Garcia-Fernandez S, Garcia-Castillo M, Melo-Cristino J, et al
    Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Int J Antimicrob Agents. 2021;57:106259.
    PubMed     Abstract available

  54. CHERNOVA OA, Chernov VM, Mouzykantov AA, Baranova NB, et al
    Antimicrobial drug resistance mechanisms among Mollicutes.
    Int J Antimicrob Agents. 2021;57:106253.
    PubMed     Abstract available

  55. XU Q, Sheng Z, Hao M, Jiang J, et al
    RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2021;57:106251.
    PubMed     Abstract available

  56. LOMBARDI F, Giacomelli A, Armenia D, Lai A, et al
    Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database.
    Int J Antimicrob Agents. 2021;57:106252.
    PubMed     Abstract available

  57. GOMEZ-JUNYENT J, Murillo O, Yu HH, Azad MAK, et al
    In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Int J Antimicrob Agents. 2021;57:106246.
    PubMed     Abstract available

    January 2021
  58. CHO YY, Kim SY, Ko KS
    A bacterial strain with the deletion of a prophage gene only in the plasmid also showed diminished antibiotic resistance.
    Int J Antimicrob Agents. 2021 Jan 30:106296.

  59. MIKKELSEN K, Sirisarn W, Alharbi O, Alharbi M, et al
    The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate beta-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids.
    Int J Antimicrob Agents. 2021 Jan 24:106283.
    PubMed     Abstract available

  60. QU J, Feng C, Li H, Lv X, et al
    Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bloodstream infection.
    Int J Antimicrob Agents. 2021 Jan 20:106284.
    PubMed     Abstract available

  61. PICCIRILLI A, Segatore B, Brisdelli F, Amicosante G, et al
    Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1(Q119X) mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales.
    Int J Antimicrob Agents. 2021;57:106228.
    PubMed     Abstract available

  62. HUANG L, Cao M, Hu Y, Zhang R, et al
    Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China.
    Int J Antimicrob Agents. 2021;57:106226.
    PubMed     Abstract available

  63. FREITAS AR, Pereira AP, Novais C, Peixe L, et al
    Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?
    Int J Antimicrob Agents. 2021;57:106227.
    PubMed     Abstract available

  64. OUCHAR MAHAMAT O, Kempf M, Lounnas M, Tidjani A, et al
    Epidemiology and prevalence of extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa.
    Int J Antimicrob Agents. 2021;57:106203.
    PubMed     Abstract available

    December 2020
  65. CHUA HC, Tse A, Smith NM, Mergenhagen KA, et al
    Combatting The Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.
    Int J Antimicrob Agents. 2020 Dec 20:106269.
    PubMed     Abstract available

  66. BIAN X, Liu X, Feng M, Bergen PJ, et al
    Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2020 Dec 19:106271.
    PubMed     Abstract available

  67. ZHANG X, Qu F, Jia W, Huang B, et al
    Polymyxin resistance in Carbapenem-resistant Enterobacteriaceae isolates from patients without polymyxin exposure a multicenter study in China.
    Int J Antimicrob Agents. 2020 Dec 18:106262.
    PubMed     Abstract available

  68. GOSTEV V, Ivanova K, Kruglov A, Kalinogorskaya O, et al
    Comparative genome analysis of global and Russian strains of community-acquired methicillin-resistant Staphylococcus aureus sequence type 22, a "Gaza clone".
    Int J Antimicrob Agents. 2020 Dec 13:106264.
    PubMed     Abstract available

    November 2020
  69. LEE NY, Lo CL, Chen PL, Syue LS, et al
    Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteremia.
    Int J Antimicrob Agents. 2020 Nov 29:106250.
    PubMed     Abstract available

    October 2020
  70. ANCILLOTTI M, Stefan Eriksson S, Andersson DI, Godskesen T, et al
    Preferences regarding antibiotic treatment and the role of antibiotic resistance: a discrete choice experiment.
    Int J Antimicrob Agents. 2020 Oct 17:106198.
    PubMed     Abstract available

  71. GELADARI A, Simitsopoulou M, Antachopoulos C, Roilides E, et al
    Immunomodulatory Effects of Colistin on Host Responses against Carbapenem-resistant Klebsiella pneumoniae Biofilms.
    Int J Antimicrob Agents. 2020 Oct 9:106182.
    PubMed     Abstract available

  72. CAMARGO CH, Cunha MPV, de Barcellos TAF, Bueno MS, et al
    Genomic and phenotypic characterization of antimicrobial resistance in carbapenem-resistant Acinetobacter baumannii hyperendemic clones CC1, CC15, CC79, and CC25.
    Int J Antimicrob Agents. 2020 Oct 9:106195.
    PubMed     Abstract available

    September 2020
  73. CLARK JA, Kulengowski B, Burgess DS
    In-Vitro Activity of Eravacycline Compared to Tigecycline and Carbapenem-resistant Enterobacteriaceae.
    Int J Antimicrob Agents. 2020 Sep 24:106178.
    PubMed     Abstract available

  74. SUTERA V, Hennebique A, Lopez F, Fernandez N, et al
    Genomic trajectories to fluoroquinolone resistance in Francisella tularensis subsp. holarctica strain LVS.
    Int J Antimicrob Agents. 2020 Sep 7:106153.
    PubMed     Abstract available

    August 2020
  75. SEO H, Lee SC, Chung H, Ra SH, et al
    Clinical and Microbiologic Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Int J Antimicrob Agents. 2020 Aug 2:106126.
    PubMed     Abstract available

  76. WARETH G, Linde J, Hammer P, Nguyen NH, et al
    Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam.
    Int J Antimicrob Agents. 2020 Aug 1:106127.
    PubMed     Abstract available

  77. IANNACCONE M, Boattini M, Bianco G, Cavallo R, et al
    Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2020;56:106066.

  78. ANDRE-GARNIER E, Hingrat QL, Marcelin AG, Reliquet V, et al
    Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
    Int J Antimicrob Agents. 2020;56:106039.

    July 2020
  79. MOWLABOCCUS S, Daley D, Pang S, Gottlieb T, et al
    Identification and Characterisation of Fosfomycin Resistance in Escherichia coli Urinary Tract Infection Isolates from Australia.
    Int J Antimicrob Agents. 2020 Jul 30:106121.
    PubMed     Abstract available

  80. MOHD SAZLLY LIM S, Naicker S, Ayfan AK, Zowawi H, et al
    Non-polymyxin based combinations as potential alternatives in treatment against carbapenem-resistant Acinetobacter baumannii infections.
    Int J Antimicrob Agents. 2020 Jul 25:106115.
    PubMed     Abstract available

  81. SUN ZL, Sun SC, He JM, Lan JE, et al
    Synergism of sophoraflavanone G with norfloxacin against effluxing antibiotic-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2020 Jul 21:106098.
    PubMed     Abstract available

  82. NGUYEN HM, Graber CJ
    A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of "Bad Bugs, Few Drugs".
    Int J Antimicrob Agents. 2020 Jul 10:106085.
    PubMed     Abstract available

  83. MARTINS WMBS, Seco BMS, Sampaio JLM, Sands K, et al
    Detection of BKC-1 in Citrobacter freundii: A clue to mobilisation in an IncQ1 plasmid carrying blaBKC-1.
    Int J Antimicrob Agents. 2020;56:106042.

  84. HSU CY, Chen FJ, Huang WC, Liao YC, et al
    Plasmid- and chromosome-located mcr-3 in mcr-1-positive Escherichia coli in Taiwan.
    Int J Antimicrob Agents. 2020;56:105996.

  85. FURLAN JPR, Savazzi EA, Stehling EG
    Widespread high-risk clones of multidrug-resistant extended-spectrum beta-lactamase-producing Escherichia coli B2-ST131 and F-ST648 in public aquatic environments.
    Int J Antimicrob Agents. 2020;56:106040.
    PubMed     Abstract available

  86. PEREZ-VAZQUEZ M, Sola-Campoy PJ, Zurita AM, Avila A, et al
    Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2.
    Int J Antimicrob Agents. 2020;56:106026.
    PubMed     Abstract available

  87. SANTORO MM, Fornabaio C, Malena M, Galli L, et al
    Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Int J Antimicrob Agents. 2020;56:106027.
    PubMed     Abstract available

  88. GAURAV A, Kothari A, Omar BJ, Pathania R, et al
    Assessment of polymyxin B-doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia.
    Int J Antimicrob Agents. 2020;56:106022.
    PubMed     Abstract available

  89. BARBOSA F, Pinto E, Kijjoa A, Pinto M, et al
    Targeting antimicrobial drug resistance with marine natural products.
    Int J Antimicrob Agents. 2020;56:106005.
    PubMed     Abstract available

  90. WILLCOCKS SJ, Cia F, Francisco AF, Wren BW, et al
    Revisiting aminocoumarins for the treatment of melioidosis.
    Int J Antimicrob Agents. 2020;56:106002.
    PubMed     Abstract available

  91. CHEN L, Han D, Tang Z, Hao J, et al
    Co-existence of the oxazolidinone resistance genes cfr and optrA on two transferable multi-resistance plasmids in one Enterococcus faecalis isolate from swine.
    Int J Antimicrob Agents. 2020;56:105993.
    PubMed     Abstract available

  92. KAVANAUGH LG, Flanagan JN, Steck TR
    Reciprocal antibiotic collateral sensitivity in Burkholderia multivorans.
    Int J Antimicrob Agents. 2020;56:105994.
    PubMed     Abstract available

  93. DOGAN O, Yesilkaya A, Menekse S, Guler O, et al
    Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
    Int J Antimicrob Agents. 2020;56:105992.
    PubMed     Abstract available

  94. NOEL A, Attwood M, Bowker K, MacGowan A, et al
    The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection.
    Int J Antimicrob Agents. 2020;56:105985.
    PubMed     Abstract available

  95. STRAZZULLA A, Iordache L, de Pontfarcy A, Pitsch A, et al
    beta-Lactam allergy and risk of multidrug-resistant bacteria in the intensive care unit: A cohort study.
    Int J Antimicrob Agents. 2020;56:105979.
    PubMed     Abstract available

  96. CAI T, Tamanini I, Mattevi D, Verze P, et al
    Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study.
    Int J Antimicrob Agents. 2020;56:105935.
    PubMed     Abstract available

    Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance.
    Int J Antimicrob Agents. 2020;56:105562.
    PubMed     Abstract available

    June 2020
  98. LAURENT S, Zakham F, Bertelli C, Merz L, et al
    Genome sequencing of Mycobacterium tuberculosis clinical isolates revealed isoniazid resistance mechanisms undetected by conventional molecular methods.
    Int J Antimicrob Agents. 2020 Jun 27:106068.
    PubMed     Abstract available

  99. SU YC, Hung WW, Lin JM, Chang CC, et al
    Tracking the evolution of the two successful CC59 methicillin-resistant Staphylococcus aureus clones in Taiwan: the divergence time of the two clades was estimated to be 1980s.
    Int J Antimicrob Agents. 2020 Jun 13:106047.
    PubMed     Abstract available

  100. LIAO W, Quan J, Liu L, Zhao D, et al
    New insights into the mechanisms of colistin resistance in Klebsiella aerogenes of clinical origin.
    Int J Antimicrob Agents. 2020;55:105990.

  101. MAJEWSKI P, Majewska P, Gutowska A, Piszcz J, et al
    Molecular characterisation of clinical pandrug-resistant Alcaligenes faecalis strain MUB14.
    Int J Antimicrob Agents. 2020;55:105939.

  102. LI R, Cheng J, Dong H, Li L, et al
    Emergence of a novel conjugative hybrid virulence multidrug-resistant plasmid in extensively drug-resistant Klebsiella pneumoniae ST15.
    Int J Antimicrob Agents. 2020;55:105952.
    PubMed     Abstract available

  103. MOURE Z, Lara N, Marin M, Sola-Campoy PJ, et al
    Interregional spread in Spain of linezolid-resistant Enterococcus spp. isolates carrying the optrA and poxtA genes.
    Int J Antimicrob Agents. 2020;55:105977.
    PubMed     Abstract available

  104. SANZ-GARCIA F, Sanchez MB, Hernando-Amado S, Martinez JL, et al
    Evolutionary landscapes of Pseudomonas aeruginosa towards ribosome-targeting antibiotic resistance depend on selection strength.
    Int J Antimicrob Agents. 2020;55:105965.
    PubMed     Abstract available

  105. ZIGANSHYNA S, Guttenberger A, Lippmann N, Schulz S, et al
    Tetrahydroporphyrin-tetratosylate (THPTS)-based photodynamic inactivation of critical multidrug-resistant bacteria in vitro.
    Int J Antimicrob Agents. 2020;55:105976.
    PubMed     Abstract available

  106. LEE YT, Sun JR, Wang YC, Chiu CH, et al
    Multicentre study of risk factors for mortality in patients with Acinetobacter bacteraemia receiving colistin treatment.
    Int J Antimicrob Agents. 2020;55:105956.
    PubMed     Abstract available

  107. XIE J, Roberts JA, Lipman J, Cai Y, et al
    Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations.
    Int J Antimicrob Agents. 2020;55:105943.
    PubMed     Abstract available

  108. WACHARACHAISURAPOL N, Phasomsap C, Sukkummee W, Phaisal W, et al
    Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients.
    Int J Antimicrob Agents. 2020;55:105940.
    PubMed     Abstract available

  109. ZHAO C, Wistrand-Yuen P, Lagerback P, Tangden T, et al
    Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data.
    Int J Antimicrob Agents. 2020;55:105941.
    PubMed     Abstract available

  110. DE LAGARDE M, Larrieu C, Praud K, Lallier N, et al
    Spread of multidrug-resistant IncHI1 plasmids carrying ESBL gene blaCTX-M-1 and metabolism operon of prebiotic oligosaccharides in commensal Escherichia coli from healthy horses, France.
    Int J Antimicrob Agents. 2020;55:105936.
    PubMed     Abstract available

    May 2020
  111. SILVA V, Miranda C, Antao HS, Guimaraes J, et al
    Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis.
    Int J Antimicrob Agents. 2020 May 18:106021.
    PubMed     Abstract available

  112. JEAN SS, Ko WC, Hsueh PR
    Susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum beta-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from the Antimicrobial Testing Leadership and Surv
    Int J Antimicrob Agents. 2020 May 15:106016.
    PubMed     Abstract available

  113. BODENDOERFER E, Marchesi M, Imkamp F, Courvalin P, et al
    Co-occurrence of aminoglycoside and beta-lactam resistance mechanisms in aminoglycoside- non-susceptible Escherichia coli isolated in the Zurich area, Switzerland.
    Int J Antimicrob Agents. 2020 May 15:106019.
    PubMed     Abstract available

  114. CASTANHEIRA M, Doyle TB, Hubler C, Sader HS, et al
    Ceftazidime-Avibactam Activity against a Challenge Set of Carbapenem-Resistant Enterobacterales: Ompk36 L3 Alterations and beta-Lactamases with Ceftazidime Hydrolytic Activity Lead to Elevated MIC Values.
    Int J Antimicrob Agents. 2020 May 14:106011.
    PubMed     Abstract available

  115. ARCAY RM, Suarez-Bode L, Lopez-Causape C, Oliver A, et al
    Corrigendum to ``Emergence of high level and stable metronidazole resistance in Clostridioides difficile'' [International Journal of Antimicrobial Agents Vol. 55 (2020) 5830].
    Int J Antimicrob Agents. 2020 May 4:105991.

  116. LO SCIUTO A, Cervoni M, Stefanelli R, Mancone C, et al
    Effect of lipid A aminoarabinosylation on Pseudomonas aeruginosa colistin resistance and fitness.
    Int J Antimicrob Agents. 2020;55:105957.
    PubMed     Abstract available

  117. JEANVOINE A, Bouxom H, Leroy J, Gbaguidi-Haore H, et al
    Resistance to third-generation cephalosporins in Escherichia coli in the French community: The times they are a-changin'?
    Int J Antimicrob Agents. 2020;55:105909.
    PubMed     Abstract available

    April 2020
  118. CHENG JW, Liu C, Kudinha T, Xiao M, et al
    The tcdA negative and tcdB positive Clostridium difficile ST81 clone exhibits high-level fluoroquinolone resistance: a multi-center study in Beijing, China.
    Int J Antimicrob Agents. 2020 Apr 21:105981.
    PubMed     Abstract available

  119. VINUE L, Sater MRA, Herriott IC, Huntley MH, et al
    Plasmids and genes contributing to high-level quinolone resistance in Escherichia coli.
    Int J Antimicrob Agents. 2020 Apr 21:105987.
    PubMed     Abstract available

  120. KRESKEN M, Korber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, et al
    Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Int J Antimicrob Agents. 2020 Apr 20:105959.
    PubMed     Abstract available

  121. ZHU YC, Barat SA, Borroto-Esoda K, Angulo D, et al
    Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor).
    Int J Antimicrob Agents. 2020;55:105922.

  122. SUZUKI Y, Sato T, Fukushima Y, Nakajima C, et al
    Contribution of beta-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.
    Int J Antimicrob Agents. 2020;55:105919.
    PubMed     Abstract available

  123. GENESTET C, Hodille E, Berland JL, Ginevra C, et al
    Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France.
    Int J Antimicrob Agents. 2020;55:105912.
    PubMed     Abstract available

  124. NISHIDA S, Ono Y
    Genomic analysis of a pan-resistant Klebsiella pneumoniae sequence type 11 identified in Japan in 2016.
    Int J Antimicrob Agents. 2020;55:105854.
    PubMed     Abstract available

    March 2020
  125. EMERAUD C, Villageois-Tran K, Genel N, Surgers L, et al
    Characterisation of incompatibility groups and plasmid addiction systems in a collection of multiresistant-producing Klebsiella pneumoniae strains.
    Int J Antimicrob Agents. 2020;55:105855.

    February 2020
  126. GONDIL VS, Harjai K, Chhibber S
    Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections.
    Int J Antimicrob Agents. 2020;55:105844.
    PubMed     Abstract available

  127. FOURNIER C, Aires-de-Sousa M, Nordmann P, Poirel L, et al
    Occurrence of CTX-M-15- and MCR-1-producing Enterobacterales in pigs in Portugal: Evidence of direct links with antibiotic selective pressure.
    Int J Antimicrob Agents. 2020;55:105802.
    PubMed     Abstract available

  128. PEYRUSSON F, Van Wessem A, Dieppois G, Van Bambeke F, et al
    Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells.
    Int J Antimicrob Agents. 2020;55:105848.
    PubMed     Abstract available

  129. YANG F, Yan J, Zhang J, van der Veen S, et al
    Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China.
    Int J Antimicrob Agents. 2020;55:105846.
    PubMed     Abstract available

  130. MIZRAHI A, Delerue T, Morel H, Le Monnier A, et al
    Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative review.
    Int J Antimicrob Agents. 2020;55:105834.
    PubMed     Abstract available

    January 2020
  131. LIU D, Song H, Ke Y, Xia J, et al
    Co-existence of two novel phosphoethanolamine transferase gene variants in Aeromonas jandaei from retail fish.
    Int J Antimicrob Agents. 2020;55:105856.
    PubMed     Abstract available

  132. BENCHETRIT L, Mathy V, Armand-Lefevre L, Bouadma L, et al
    Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases.
    Int J Antimicrob Agents. 2020;55:105842.

  133. PANG S, Boan P, Lee T, Gangatharan S, et al
    Linezolid-resistant ST872 Enteroccocus faecium harbouring optrA and cfr (D) oxazolidinone resistance genes.
    Int J Antimicrob Agents. 2020;55:105831.

  134. ZHANG M, Yan H, Lu M, Wang D, et al
    Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence.
    Int J Antimicrob Agents. 2020;55:105804.
    PubMed     Abstract available

  135. LI R, Xie M, Liu L, Huang Y, et al
    Characterisation of a cointegrate plasmid harbouring blaNDM-1 in a clinical Salmonella Lomita strain.
    Int J Antimicrob Agents. 2020;55:105817.
    PubMed     Abstract available

  136. LIU Z, Xiao X, Liu Y, Li R, et al
    Recombination of NDM-5-producing plasmids mediated by IS26 among Escherichia coli.
    Int J Antimicrob Agents. 2020;55:105815.

  137. GAIBANI P, Ambretti S, Campoli C, Viale P, et al
    Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime/avibactam carrying a novel KPC variant (KPC-36).
    Int J Antimicrob Agents. 2020;55:105816.

  138. MEURER L, Payne W, Guffey JS
    Visible light as an inhibitor of Campylobacter jejuni.
    Int J Antimicrob Agents. 2020;55:105818.
    PubMed     Abstract available

  139. PEREZ-CANTERO A, Lopez-Fernandez L, Guarro J, Capilla J, et al
    Azole resistance mechanisms in Aspergillus: update and recent advances.
    Int J Antimicrob Agents. 2020;55:105807.
    PubMed     Abstract available

  140. LI XP, Sun RY, Song JQ, Fang LX, et al
    Within-host heterogeneity and flexibility of mcr-1 transmission in chicken gut.
    Int J Antimicrob Agents. 2020;55:105806.
    PubMed     Abstract available

  141. CASTANHEIRA M, Deshpande LM, Messer SA, Rhomberg PR, et al
    Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Int J Antimicrob Agents. 2020;55:105799.
    PubMed     Abstract available

    November 2019
  142. ZYKOV IN, Frimodt-Moller N, Smabrekke L, Sundsfjord A, et al
    The efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
    Int J Antimicrob Agents. 2019 Nov 23. pii: S0924-8579(19)30322.
    PubMed     Abstract available

    September 2019
  143. BARRAUD O, Ravry C, Francois B, Daix T, et al
    Shotgun metagenomics for microbiome and resistome detection in septic patients with urinary tract infections.
    Int J Antimicrob Agents. 2019 Sep 16. pii: S0924-8579(19)30252.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.